Abstract: An example method of virtualizing a hardware accelerator in a host cluster of a virtualized computing system includes: commanding, at an initiator host in the host cluster, a programmable expansion bus device to reconfigure as a virtual accelerator based on specifications of a hardware accelerator in a target host of the host cluster; executing, in the programmable expansion bus device, software to emulate the virtual accelerator as connected to an expansion bus of the initiator host; receiving, at the programmable expansion bus device, compute tasks from an application executing in the initiator host; and sending, to the target host, the compute tasks for processing by the hardware accelerator.

Abstract: This disclosure is directed to automated processes for attesting to trustworthiness of a host considered for connection to a data center network. The attestation process is performed in two attestation phases. In the first phase, attestation is performed on a smart network interface controller (“SNIC”) connected to an internal bus of the host using a first trusted platform module (“TPM”) of the SNIC. In the second phase, attestation is performed on the host by the SNIC using a second TPM connected to the internal bus of the host in response to a determination that the SNIC is trustworthy. The host is connected to the data center network in response to a determination by the SNIC that the host is trustworthy.

Abstract: The present invention provides novel methods and systems, including cell lines, recombinant polynucleotide constructs, compositions, and kits, for targeted yet universal genomic manipulation.

Abstract: The present disclosure describes systems and methods for immunotherapies Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors). The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.

Abstract: The present invention provides novel methods and systems, including cell lines, recombinant polynucleotide constructs, compositions, and kits, for targeted yet universal genomic manipulation.